文献速递儿童内分泌与遗传代谢儿童心血管与肾脏儿童神经与发育行为

三例晚发型糖原贮积症Ⅱ型伴肥厚性心肌病临床与基因突变分析

[Clinical and gene mutation analysis of three children with late-onset glycogen storage disease type Ⅱ with hypertrophic cardiomyopathy].
PubMed 文献 · Zhonghua Er Ke Za Zhi · 2017-01-01

该研究报告3例以运动发育迟缓、肌无力伴肥厚性心肌病起病的晚发型糖原贮积症Ⅱ型患儿,干血滤纸片法显示酸性GAA活性分别为2.65、3.55和1.51 pmol/(punch·h),正常对照8.00~98.02。基因分析发现5种GAA致病突变,体外功能研究显示5种突变型酶活性仅为野生型的9.9%~22.5%,蛋白表达量为野生型的32.0%~63.9%。

要点

  • 晚发型GSDⅡ可表现为肌无力伴肥厚性心肌病,心功能可处于代偿期。
  • 3例患儿酸性GAA活性均低于正常对照范围。
  • 5种GAA突变体外均导致酶活性和蛋白表达下降。

核心结论

  • 3例晚发型GSDⅡ患儿除四肢肌无力外均有明显肥厚性心肌病,心功能尚处于代偿期。
  • 共发现5种GAA基因致病突变,体外功能分析显示5种突变均可导致GAA活性降低和蛋白表达量下降。

研究设计与样本

  • 纳入2011—2016年上海交通大学医学院附属新华医院小儿内分泌/遗传门诊就诊的3例晚发型GSDⅡ患儿。
  • 采用干血滤纸片法检测GAA活性,PCR产物直接测序法检测GAA基因突变。
  • 构建5种突变型GAA质粒,与野生型质粒瞬时转染293T细胞,测定GAA活性并用western blot检测蛋白表达。

主要发现

  • 3例患儿分别在3岁或1岁6个月出现运动发育迟缓、肌无力伴肥厚性心肌病。
  • 3例患儿酸性GAA活性分别为2.65、3.55和1.51 pmol/(punch·h),正常对照为8.00~98.02。
  • GAA基因分析发现3例患儿携带5种致病突变:p.G478R、p.P361L、p.P266S、p.Q323X、p.R672Q。
  • 体外表达研究显示5种突变型酶活性只有野生型的9.9%~22.5%。
  • 5种突变型蛋白表达量与野生型相比只有32.0%~63.9%。

关键数值与推荐

  • 3例患儿酸性GAA活性分别为2.65、3.55和1.51 pmol/(punch·h),正常对照8.00~98.02。
  • 5种突变型酶活性为野生型的9.9%~22.5%,蛋白表达量为野生型的32.0%~63.9%。

临床怎么用

  • 对运动发育迟缓、肌无力伴肥厚性心肌病的儿童,应考虑晚发型GSDⅡ并检测GAA活性。
  • GAA基因测序可协助明确致病突变,体外功能分析有助于判断突变对酶活性和蛋白表达的影响。

局限性

  • 本研究仅纳入3例患儿,样本量小。
  • 突变功能分析为体外293T细胞实验,不能完全反映体内情况。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To investigate the clinical and laboratory features of three children with late-onset type Ⅱ glycogen storage disease(GSD) who presented with hypertrophic cardiomyopathy and to analyze the effect of five mutations identified on the acid-α-glucosidase (GAA) activity and stability. Method: Three cases of children with muscle weakness were included in this study.GAA activity was analyzed in Dried Blood Spot of the patients.DNA was extracted from peripheral blood in all the patients and their parents and subjected to polymerase chain reaction and directly sequencing of GAA gene.Five mutant pcDNA3.1-myc-his-GAA expression plasmids(p.G478R, p.P361L, p.P266S, p.Q323X, p.R672Q) were constructed and transient instantaneously transfected into 293T cells to analyze the enzyme activity and stability of GAA. Result: All the three children had the onset of disease at 3 years or 1.5 years of age.They presented with developmental delay, muscle weakness and hypertrophic cardiomyopathy.GAA activity of 3 patients was 2.65, 3.55 and 1.51 pmol(punch·h)(8.00-98.02)respectively. Genetic analysis found 5 mutations (p.G478R, p. P361L, p. P266S, p. Q323X, p. R672Q), and all of these 3 cases had clinical manifestations and were diagnosed as late-onset type Ⅱ glycogen storage disease.Five mutant pcDNA3.1-myc-his-GAA expression plasmids were transfected into 293T cells.Five mutant enzyme activities were found to be only 9.9%-22.5% of the wild-type enzyme activity and the protein expression of the five mutants was 32.0%-63.9% compared with the wild type. Conclusion: This study reports 3 children with late-onset GSD Ⅱ accompanied by hypertrophic cardiomyopathy and compensatory stage of cardiac function in addition to limb muscle weakness.Five pathogenic mutations were identified, and these 5 mutations result in decreased GAA activity and GAA expression by in vitro functional analysis. 目的: 分析伴有肥厚性心肌病的晚发型糖原贮积症Ⅱ型的临床和基因突变特点。 方法: 对2011—2016年上海交通大学医学院附属新华医院小儿内分泌/遗传门诊就诊的3例晚发型糖原贮积症Ⅱ型患儿,分析其临床和实验室特点,干血滤纸片法检测其葡聚糖1,4-α-葡萄糖苷酶(GAA)活性,PCR产物直接测序法进行GAA基因突变的检测。对所发现的5种突变构建突变型GAA质粒,将野生型质粒与突变型质粒瞬时转染293T细胞,测定突变型及野生型GAA活性,western blot检测野生型及突变型GAA蛋白在293T细胞中的表达并进行统计学分析。 结果: 3例患儿分别在3岁或1岁6个月出现运动发育迟缓、肌无力伴肥厚性心肌病,其酸性GAA活性分别为2.65、3.55和1.51 pmol/(punch·h)(正常对照8.00~98.02)。GAA基因分析发现3例患儿携带5种致病突变(p.G478R,p.P361L,p.P266S,p.Q323X,p.R672Q)。结合临床3例患儿诊断为晚发型糖原贮积症Ⅱ型。对所发现的5种突变进行体外表达和功能研究,发现5种突变型酶活性只有野生型酶活性的9.9%~22.5%,5种突变型的蛋白表达量与野生型相比,只有野生型的32.0%~63.9%。 结论: 3例晚发型糖原贮积症Ⅱ型患儿,临床表现为四肢肌无力,均有明显的肥厚性心肌病,心功能尚处于代偿期。共发现5种GAA基因致病突变,5种突变均可导致GAA活性降低和蛋白表达量下降。.

来源:Zhonghua Er Ke Za Zhi,查看原文。版权归原作者所有。

引用

  1. Luo JH, Qiu WJ, Fang D, et al. [Clinical and gene mutation analysis of three children with late-onset glycogen storage disease type Ⅱ with hypertrophic cardiomyopathy]. Zhonghua Er Ke Za Zhi. 2017. PMID: 28592009. doi:10.3760/cma.j.issn.0578-1310.2017.06.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。